ArticleJournal of molecular histology2025
Myoinositol improves sperm parameters in diabetic rats by reducing oxidative stress and regulating apoptosis-related genes.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptomic profiling reveals tissue-specific and sex-dimorphic lipid storage in Bufo gargarizans.BMC genomics · 2025Article
- Diabetic testicular dysfunction and spermatogenesis impairment: mechanisms and therapeutic prospects.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes disrupts spermatogenesis and leads to low-quality sperm by causing oxidative stress, inducing apoptosis and reducing testosterone level. Myoinositol has antiglycemic, antioxidant, anti-apoptotic, and testosterone-regulating properties. This study aimed to evaluate the potential of myoinositol in improving sperm production and sperm quality in diabetic rats. Eighteen rats were divided into three groups (n = 6 per group): control, diabetic (Streptozotocin + Nicotinamide), and diabetic + myoinositol supplementation (300 mg/kg, for 56 days). Sperm parameters, including count, total motility, viability, and morphology, were evaluated. Additionally, several biochemical and molecular markers were measured including serum malondialdehyde (MDA), superoxide dismutase (SOD), total antioxidant capacity (TAC), testosterone, Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), and Bax/Bcl2 gene expression ratio, Bax and Bcl2 protein expression, germinal epithelium apoptosis. In the diabetic group, sperm count, viability, and normal morphology significantly decreased, along with lower levels of SOD, TAC, testosterone, FSH, and LH. Conversely, MDA levels and the Bax/Bcl2 gene ratio significantly increased compared to the control group. In the diabetic + myoinositol group, sperm count, viability, morphology, and motility significantly improved (P < 0.001), as did TAC, testosterone, and FSH levels (P < 0.001), with a significant increase in LH levels (P < 0.05). Additionally, MDA levels (P < 0.01) and the Bax/Bcl2 gene ratio (P < 0.05) were significantly reduced compared to the diabetic group. This study showed that diabetes impairs sperm quality, antioxidant capacity, and hormones while increasing oxidative stress and apoptosis. Myoinositol improves sperm parameters, boosts antioxidants, and reduces apoptosis, suggesting its therapeutic potential for diabetes-induced reproductive dysfunction.
Indexed as
Identifiers
40397159What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.